ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.

AIM Profiling the efficacy and pharmacodynamic activity of the kinesin spindle protein (KSP) inhibitor ARRY-520 will aid the identification of responsive tumor types and pharmacodynamic profiles that correlate with activity. MATERIALS AND METHODS In vivo activity was evaluated in a diverse panel of 16 different tumor xenograft models. Pharmacodynamic activity was evaluated in selected models. RESULTS ARRY-520 had low nanomolar antiproliferative activity in tumor cell lines. Monopolar spindles were formed at active potencies. Partial or complete responses were observed in 13/16 xenograft models. Hematological tumors were particularly sensitive, with a 100% complete response rate in some models. Maintenance of mitotic block for a sufficient length of time for cells to lose survival signals and progress to apoptosis was a key component of the mechanism of activity. ARRY-520 was also active in several taxane resistant models. CONCLUSION The data provide a rationale for clinical evaluation of the activity of ARRY-520 in hematological carcinomas and taxane-resistant tumors.

[1]  Z. Estrov,et al.  A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Taylor,et al.  Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit , 2009, Molecular Cancer Therapeutics.

[3]  C. Akgul.  Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[4]  M. Grever,et al.  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. , 2009, Blood.

[5]  A. Giannis,et al.  Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications , 2008, Clinical Cancer Research.

[6]  J. Leonard,et al.  A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB- 743921 Administered on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma. , 2008 .

[7]  P. Morris,et al.  Microtubule Active Agents: Beyond the Taxane Frontier , 2008, Clinical Cancer Research.

[8]  B. Tunquist,et al.  447 POSTER ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma , 2008 .

[9]  Conly L. Rieder,et al.  Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied , 2008, The Journal of cell biology.

[10]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[11]  M. Blagosklonny.  Mitotic Arrest and Cell Fate: Why and How Mitotic Inhibition of Transcription Drives Mutually Exclusive Events , 2007, Cell cycle.

[12]  C. Takimoto,et al.  640 POSTER Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors , 2006 .

[13]  M. Miglarese,et al.  Development of new cancer therapeutic agents targeting mitosis , 2006, Expert opinion on investigational drugs.

[14]  G. Chin,et al.  Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint , 2006, Molecular Cancer Therapeutics.

[15]  Conly L. Rieder,et al.  Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint , 2006, Current Biology.

[16]  A. Razak,et al.  Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Weikang Tao,et al.  Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. , 2005, Cancer cell.

[18]  R. Bataille,et al.  Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival , 2005, Leukemia.

[19]  Lawrence C Kuo,et al.  Inhibition of a mitotic motor protein: where, how, and conformational consequences. , 2004, Journal of molecular biology.

[20]  R. Agami,et al.  Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension , 2003, The EMBO journal.

[21]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[22]  S. Edwards,et al.  In vivo localisation and stability of human Mcl‐1 using green fluorescent protein (GFP) fusion proteins , 2000, FEBS letters.

[23]  D. Scudiero,et al.  Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. , 1998, Journal of the National Cancer Institute.

[24]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[25]  C. Beattie,et al.  Human breast carcinoma cell lines: ultrastructural, genotypic, and immunocytochemical characterization. , 1992, Anticancer research.

[26]  A. Tulpule,et al.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.

[27]  T. Tsuruo,et al.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. , 1986, Japanese journal of cancer research : Gann.

[28]  M. Harrison,et al.  Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. , 2009, Clinical advances in hematology & oncology : H&O.

[29]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.